Recent studies have uncovered the use of specific biomarkers for the sole purpose of isolating and diagnosing CeD pathogenesis, and include immunogenic gluten peptides (specifically 33-mer gliadin peptide) and deamidated gliadin peptides (DGP), as well as antibodies exclusive to CeD subjects only; anti-gliadin antibody (AGA), anti-endomysial antibody (AEA), anti-tissue transglutaminase (anti-tTG–TG2, TG6, TG3) and the neo-epitopes (modification to the antigenic determinant) tTG-DGP complex [235]. This evidence concerns the gene TGM2 and cranioectodermal dysplasia.